TG-1101 is a highly potent next generation glycoengineered anti-CD20 monoclonal antibody to ibrutinib monotherapy in high risk CLL. The multicenter GENUINE trial, which evaluated the efficacy and safety of
The UK's Competition and Markets Authority (CMA) said both the firms entered into agreements under which Actavis UK incentivised Concordia not to enter the market with its own
Under the deal, the companies will jointly develop and commercialise MEDI8897, a highly potent monoclonal antibody (mAb) that neutralises RSV by binding the RSV fusion (F) protein expressed on
The study demonstrated that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen) reduced risk of recurrence of invasive disease or death (invasive disease-free survival) in people
The study evaluated the efficacy of Blincyto versus standard of care (SOC) chemotherapy in high-risk adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia
The positive top-line results from the trial showed the treatment effect of axicabtagene ciloleucel in a patient population of 101 having multiple types of aggressive NHL, said Kite
EMD Serono is the biopharmaceutical business of Merck in the US and Canada. The BLA has been accepted for Merck and Pfizer's avelumab to treat patients with locally advanced or mUC with
In the phase 3 trial dubbed ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) in 344 catecholamine resistant hypotension patients, LJPC-501 demonstrated positive top-line results. The percentage
The companies will establish a joint venture (JV) and each share equally in the initial investment. Subject to necessary regulatory approvals, the construction on the initial phase of the facility
An approval from EMA would make the drug available for the treatment of hyperkalaemia in all the 28 member states of the European Union along with Iceland, Liechtenstein
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.